©The Author(s) 2025.
World J Exp Med. Dec 20, 2025; 15(4): 111542
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.111542
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.111542
Table 1 Comparison of baseline demographic, clinical and biochemical characteristics of the two study groups, n (%)
| Characteristic | Group A (n = 25) | Group B (n = 25) | P value |
| Age (years) (mean ± SD) | 49.48 ± 5.83 | 52.12 ± 4.28 | 0.07 |
| Male | 20 (80) | 20 (80) | > 0.99 |
| Body mass index (kg/m2) (mean ± SD) | 25.57 ± 5.59 | 23.86 ± 4.75 | 0.25 |
| Cardiovascular disease risk factors and disease characteristics | |||
| Smoking | 16 (64) | 21(84) | 0.20a |
| Alcohol | 13 (52) | 11 (44) | 0.78 |
| Oedema | 05 (20) | 10 (40) | 0.22 |
| Dyspnea on exertion | 18 (72) | 18 (72) | > 0.99 |
| Orthopnea | 13 (52) | 17 (68) | 0.39 |
| Paroxysmal nocturnal dyspnea | 01 (04) | 08 (32) | 0.02a |
| Medical history | |||
| Diabetes mellitus | 05 (20) | 03 (12) | 0.70 |
| Hypertension | 10 (40) | 11 (44) | > 0.99 |
| Myocardial infarction | 05 (20) | 04 (16) | 0.35 |
| Angina pectoris | 01 (4) | 02 (8) | > 0.99 |
| Stroke | - | 04 (16) | 0.11 |
| Percutaneous coronary intervention | 03 (12) | 03 (12) | > 0.99 |
| Atrial fibrillation | - | 01 (4) | > 0.99 |
| Left ventricular ejection fraction (%) (mean ± SD) | 20 ± 9.35 | 27 ± 20 | 0.6 |
| N-terminal pro-B-type natriuretic peptide (pg/mL) (mean ± SD) | 117.53 ± 38.49 | 97.37 ± 31.18 | 0.05 |
| High-sensitivity C-reactive protein (mg/L) (mean ± SD) | 6.25 ± 4.13 | 5.6436 ± 3.83 | 0.59 |
- Citation: Dhawan R, Mittal R, Kumar A, Laller KS, Gill PS, Rag A, Mittal N. Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial. World J Exp Med 2025; 15(4): 111542
- URL: https://www.wjgnet.com/2220-315x/full/v15/i4/111542.htm
- DOI: https://dx.doi.org/10.5493/wjem.v15.i4.111542